Warner, Louise
March 1963
Angiology;Mar1963, Vol. 14 Issue 3, p116
Academic Journal
The number of blood vessels per cubic millimeter of tumor tissue seems to be greatest first, when the tumor begins to grow (cf. frog I, 56th day after inoculation), and then subsides until the tumor starts to regress, when the blood vessels increase again (cf. frogs I and IV on the 84th day after inoculation). The validity of this statement can be tested in future series of animals.


Related Articles

  • Successful renal transplantation after two separate urinary tract malignancies. Joshi, Rohit; Mammen, Kim; Pawar, Basant // Indian Journal of Urology;Apr-Jun2008, Vol. 24 Issue 2, p256 

    A patient who was treated for renal cell carcinoma and transitional cell carcinoma, later presented with end stage renal disease. He was managed with hemodialysis and later underwent successful renal transplantation. There was no evidence of tumor recurrence nearly nine years post-renal...

  • Partial nephrectomy for renal cell carcinoma in an allograft kidney with limited functional reserve. Li, Jordan Y. Z.; Yong, Tuck Y.; Rao, Mohan; Coates, P. Toby H. // NDT Plus;Aug2009, Vol. 2 Issue 4, p312 

    The increased risk of malignancies is a well-recognized complication of organ transplantation. When renal cell carcinoma (RCC) occurs in kidney transplant recipients, less than 10% of it affects the allograft. Recent experience suggests that partial allograft nephrectomy for tumours less than 4...

  • Renal Cell Carcinoma in a kidney allograft 11 years after renal transplant. Taj, Asma; Muzaffar, Mehvish; Sheikh, Rehmat Ullah; Qadir, Rehana; Ratnam, Shobha // Internet Journal of Oncology;2009, Vol. 6 Issue 2, p18 

    Malignancies are common after renal transplant because of immunosuppression. Renal cell carcinoma is common but occurs in the native kidney. Carcinoma in the transplant kidney is less common but has been reported with an average interval of 3 to 4 years after transplant. We report a case of...

  • Papillary renal cell carcinoma in allograft kidney. Roy, Catherine; El Ghali, Sofiane; Buy, Xavier; Lindner, Véronique; Gangi, Afshin // European Radiology;Apr2005, Vol. 15 Issue 4, p661 

    Papillary renal cell carcinoma is a subgroup of malignant renal epithelial neoplasms. Its occurrence in allograft transplanted kidney has not been debated in the literature. We report two pathologically proven cases and discuss the clinical hypothesis for such neoplasms and the aspect on MR...

  • RENAL CELL CARCINOMA DETECTED IN A CADAVERIC DONOR BEFORE RENAL TRANSPLANTATION. Keleş, Mustafa; Uyanık, Abdullah; Polat, Yalçın; Çetinkaya, Ramazan; Aydınlı, Bülent; Gündoğdu, Cemal; Özbey, İsa // European Journal of General Medicine;2008, Vol. 5 Issue 4, p254 

    The article discusses the importance of pre-transplantation investigation for malignancy in a cadaverci donor who underwent a liver, left kidney, and heart transplantation. It cites the case of a healthy female patient who has donated her organs to her relatives, but prior to the recipient's...

  • Should small renal masses be managed expectantly? Singla, Manish; Srivastava, Aneesh // Indian Journal of Urology;Jul-Sep2007, Vol. 23 Issue 3, p331 

    In this retrospective analysis the authors have studied the short-term outcomes of patients whose renal masses were managed expectantly (i.e., watchful waiting) to provide insight into the natural history of small renal tumors. This study also analyzed the effects of delayed intervention in...

  • A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. Wei Sun; Fan, Yue Z.; Zhang, Wen Z.; Ge, Chun Y. // Journal of Experimental & Clinical Cancer Research (17569966);2011, Vol. 30 Issue 1, p46 

    Background: Vasculogenic mimicry (VM), as a new blood supply for tumor growth and hematogenous metastases, has been recently described in highly aggressive human melanoma cells, etc. We previously reported VM in human gallbladder carcinomas and its clinical significance. In this study, we...

  • Proleukin.  // Royal Society of Medicine: Medicines;2002, p456 

    This article presents information on Proleukin drug. The drug is a proprietary, prescription-only preparation of the immunomodulator drug aldesleukin. It can be used for anticancer treatment in certain patients with metastatic renal cell carcinoma. It is available in a form for injection.

  • Usefulness of CT During Renal Arteriography: A Case of Percutaneous Radiofrequency Ablation for Renal Cell Carcinoma. Tanigawa, Noboru; Kariya, Shuji; Komemushi, Atsushi; Kojima, Hiroyuki; Sawada, Satoshi // CardioVascular & Interventional Radiology;Nov/Dec2004, Vol. 27 Issue 6, p669 

    A 64-year-old man with a unilateral 15 mm diameter renal cell carcinoma underwent percutaneous radiofrequency ablation (RFA) assisted by CT during renal arteriography (angio-CT). Prior to placement of the needle electrode, a 5 Fr angio-catheter was placed in the right renal artery, and angio-CT...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics